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This research used paid claims data to investigate the
likelihood that patients achieved an adequate course of
antidepressant drug therapy and the impact of completed
therapy on health care costs. Completed therapy was
defined as six or more months of uninterrupted therapy
at an adequate dose as determined by AHCPR treat-
ment guidelines. Apparent average daily dose for each
prescription filled was calculated from data on the pre-
scription paid claim and allowances were made for titra-
tion of dose to therapeutic levels and changes in antide-
pressant therapy. A total of 1648 new episodes of
antidepressant therapy were identified for analysis. The
likelihood of achieving an adequate course of antidepres-
sant therapy was 22%. Completion rates varied signifi-
cantly across antidepressants with fluoxetine achieving
the highest completion rate at nearly 51%. Total health
care costs were significantly lower for patients who
 
completed therapy (
 

 
$1487; 
 
P
 
 
 

 
 .0487) due primarily
to lower ambulatory care costs (
 

 
$1296; 
 
P
 
 
 

 
 .0110).
Fluoxetine was the only antidepressant therapy which
exhibited significantly lower total health care cost per
patient relative to the older tricyclic antidepressants
(
 

 
$3524; 
 
P
 
 
 

 
 .0024). The total costs of treating de-
pression in the ambulatory setting were found to vary
widely across alternative antidepressants. Most of the
cost-savings associated with fluoxetine use were associ-
ated with the increased likelihood of completed therapy.
Further research is needed to verify if fluoxetine achieves
better rates of completed therapy relative to other SSRI
antidepressants using data from other settings.
 
Introduction
 
Major depressive disorder (MDD) is often under-
treated in the ambulatory medical care setting, ei-
ther because the disorder is not diagnosed by the
clinician or the patient did not receive an adequate
course of pharmacologic therapy. For example,
Wells et al. [1] found that roughly half of 650 pa-
tients with a current depressive disorder were
properly diagnosed by nonmental health special-
ists. Katon et al. [2] screened 767 patients with
high primary care utilization profiles for possible
depression. Over 44% of these patients were clas-
sified as possibly depressed, a rate far in excess of
the 6-month prevalence rate of 1% to 3% esti-
mated by Myers et al. [3]. Katon and his col-
leagues completed psychiatric interviews with 119
of these patients and found 24% to have a current
episode of major depression and 68% to have had
a lifetime history of major depression. Nearly half
of the patients interviewed by the psychiatrist
(47%) were evaluated as requiring drug therapy.
However, only 45% of these patients had received
antidepressant therapy in the previous 12 months
(unrecognized depression), of whom 11% received
an adequate course of therapy in terms of dose
and duration (under-treated depression) [4].
The failure of tricyclic antidepressants (TCAs)
to adequately treat depressed patients in the out-
patient setting is well established. For example,
in the California Medicaid (Medi-Cal) program,
nearly 80% of patients treated for depression
failed to complete 6 months of uninterrupted drug
therapy at minimum therapeutic dose [5]. In this
study, interrupted or terminated therapy was
found to increase total health care costs by over
$1000 per patient in the first post-treatment year.
Fortunately, the newer serotonin re-uptake in-
hibitors (SSRIs) offer clinicians therapeutic alter-
natives to TCAs and heterocyclic antidepressants
in the treatment of depression [6–14]. Several re-
cent empirical studies suggest that SSRI antide-
pressants are better tolerated than conventional
tricyclic and heterocyclic antidepressants by pa-
tients with major depressive disorders. These data,
which were derived from real world clinical prac-
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tice settings, imply that SSRI patients experience
lower health care costs. For example, Skaer et al.
[15] found that the paroxetine reduced health care
costs relative to TCAs in adult HMO patients
with a single episode MDD who filled at least three
antidepressant prescriptions and stayed with their
initial medication. Previously, Sclar et al. [16], had
found similar results for fluoxetine in a study of
comparable HMO patients. Building on these re-
sults, Sclar et al. [17] compared single-episode
MDD patients prescribed sertraline, paroxetine
and fluoxetine who used only the initial medica-
tion prescribed and filled a minimum of three pre-
scriptions. In this study, fluoxetine was found to
result in lower MDD-related treatment costs com-
pared to sertraline and paroxetine. In a more re-
cent study, Simon et al. [18], in a comparison of
fluoxetine to desipramine and imipramine, found
that patients initiating therapy with a TCA were
twice as likely to add a second antidepressant to
their drug regimen or switch to an alternative drug
compared to fluoxetine-treated patients.
This study used data from the Medi-Cal pro-
gram to investigate the relative performance of
SSRIs compared with the conventional tricyclic and
heterocyclic antidepressants available to Medi-Cal
recipients under the program’s drug formulary.
Three indicators of performance were investi-
gated: the length of drug therapy achieved above
minimum therapeutic dosing levels; the rate of
augmentation or switching of antidepressant ther-
apies; and health care costs by type of service for
patients using antidepressants.
 
Data
 
The data for the analysis were derived from the
Medi-Cal program, which finances a wide range
of health care services for the poor and disabled,
including outpatient prescription drugs. Medi-Cal
generates a longitudinal research database for a
random 5% sample of all recipients for as long as
the sample recipient is eligible. This database pro-
vides patient-level demographic data combined
with a summary of each claim for covered services
paid on behalf of the recipient. Data include type
of service, date of service, amount billed, amount
paid, and units (days) of service. Prescription drug
claims identify the specific product dispensed,
quantity, strength and the date the prescription
was filled. Prescription drugs are provided under
Medi-Cal subject to a $1 copayment, though anec-
dotal information suggests that the copayment is
not routinely collected by the pharmacy. Data for
this analysis were drawn from the period January
1987 to July 1996.
Medi-Cal costs in the pre- and post-treatment
periods were partitioned by type of service. The
amounts paid by Medi-Cal understate total pay-
ments incurred by elderly and disabled Medi-Cal
recipients who are dually eligible for Medicare
which becomes the primary payer for these pa-
tients. The gaps between Medi-Cal payments and
total payments for institutional care was bridged
by multiplying days of hospital, and skilled nurs-
ing facility (SNF) and intermediate care facility
(ICF) days by per diem cost estimates for these ser-
vices. Hospital days were assigned a cost of $979
per day [19], while SNF and ICF costs per day
were valued at $270 [20]. To assure consistency,
hospital and nursing home costs were estimated
for all patients in the study, not just the Medicare
eligible. In addition, the Medi-Cal cost for ambu-
latory services covered under Part B of Medicare
were used to estimate total ambulatory care costs
in both the pretreatment and post-treatment peri-
ods for all patients over 65 years of age. Actual
Medi-Cal expenditures were used for patients
under age 65. All reported noninstitutional expen-
ditures were adjusted to 1994 dollars using histor-
ical Medi-Cal specific rates of fee schedule adjust-
ments by type of service.
Providers do not routinely record diagnostic
data on their claims for Medi-Cal payment. These
omissions create two potential problems for the
analysis. First, the selection of patients for study
must be carefully crafted to focus the analysis on
major depression. Solutions to this issue are dis-
cussed below. Second, missing diagnostic data pre-
clude any attempt to limit the analyses to health
care services consumed specifically for MDD. We
do not believe that this latter limitation is relevant
to a study of depression. Conducting this analysis
using total post-treatment health care costs may
provide a more accurate estimate of the impact of
adequate dose and duration of therapy given the
effects of depression on disability days, functional
status, well-being, and the consumption of health
services related to other illnesses. For example,
Broadhead et al. [21] found that MDD increased
the risk of disability by a factor of 4.78 and in-
creased the number of disability days by 51%.
Hays et al. [22] found patients with depressive
symptoms to be comparable to or worse off in
terms of functioning and well being than patients
with eight major chronic medical conditions. Fi-
nally, Verbosky, Franco, and Zrull [23] found that
depression increased the average length of hospital
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stays by 10 days even after controlling for primary
diagnosis and severity of illness.
 
Methods
 
Inclusion and Exclusion Criteria
 
The study population was selected from patients
initiating antidepressants between 1987 to mid-
1996. A total of 12,724 new patient-episodes of
antidepressant therapy were identified as potential
study observations. Episodes of therapy were in-
cluded in the analysis if:
• More than 6 months of pretreatment and 1
year of post-treatment data were available.
• The patient did not use any antidepressant in
the 6 month pretreatment period (new episode).
• The patient was between 18 and 100 years of age.
• The patient was not institutionalized in a nurs-
ing home within 30 days of the start of therapy.
New patient-episodes of antidepressant therapy
were excluded from this sample for the following
reasons:
• The patient’s paid claims history included: (a)
a paid claim with a recorded diagnosis of
schizophrenia, mania, bipolar depression, de-
mentia, chronic or transient organic psychotic
conditions; (b) a prescription drug claim for a
mood stabilizing medication or antipsychotic
medication prior to the treatment episode; or
(c) a prescription claim for a MAO inhibitor or
for two different antidepressant medications as
initial therapy (2333 episodes, 18.3%).
• The patient’s paid claims include a gap in all
paid claims in excess of 3 months which may
indicate a temporary loss of eligibility for pa-
tients under the age of 65 (2047 episodes,
16.1%).
• The patient consumed more than $1000 in
“other” services in the 6 months prior to the
treatment episode, or more than $2000 in such
services in the 1-year post-treatment period
(1411 episodes, 11.1%).
• No diagnosis of MDD (ICD-9296.2, 296.3)
for patients taking TCAs or heterocyclic anti-
depressants (5257 episodes, 41.3%).
• The patient consumed more than 120 days of
acute hospital care or more than $100,000 in
ambulatory care in the post-treatment period,
or more than $50,000 in ambulatory care use
in the 6-month period immediately prior to the
initiation of antidepressant therapy (28 epi-
sodes, 0.2%).
The above criteria, designed to exclude patients
with schizophrenia, bipolar disorder, and other se-
vere forms of mental disorders based on either a
recorded diagnosis or use of selected psychotropic
medications, may not eliminate all of these pa-
tients from the analysis. For example, unpublished
data from an ongoing analysis conducted by the
authors into the cost of treating schizophrenia in-
dicate that these patients may forego active ther-
apy with antipsychotic medications for extended
periods of time. It is also likely that these patients
will have been treated with TCA antidepressants
rather than the newer SSRI medications, leaving
open the possibility that the TCA/MDD popula-
tion is more likely to include patients with severe
mental illnesses.
The significant loss of episodes due to a missing
diagnosis of MDD is not surprising given the low
rate of recording diagnosis on claims for payment
by Medi-Cal providers. This exclusion criteria was
necessary since tricyclic and heterocyclic antide-
pressants may be used to treat other nonmental dis-
orders (e.g., sleep disorders, chronic pain). Since the
therapeutic dose required to treat these medical
conditions adequately is far below the minimum
dose required for depression, including these non-
MDD patients would bias downward the appar-
ent treatment completion rates in the TCA and
heterocyclic antidepressant populations. However,
excluding TCA and heterocyclic patients without
an MDD diagnosis could introduce bias into the
analysis if the recording of the MDD diagnosis is
correlated with the likelihood of treatment com-
pletion or future health care costs. While there is
no evidence that this is the case, this limitation
should be considered when evaluating the results
of this analysis.
Fluoxetine, sertraline, and paroxetine were sub-
ject to prior authorization limiting their use to
MDD. Therefore, for the primary analyses reported
here, all patients treated with these medications
were not required to have an MDD diagnosis re-
corded on their paid claims data. A sensitivity anal-
ysis was conducted in which only MDD patients
were included. The drugs included for study and
data on the final sample available for analysis are
presented in Table 1.
 
Definition of Adequate Dose and Duration of Therapy
 
The guidelines for the treatment of depression de-
veloped by the Agency for Health Care Policy and
Research [24] were used as a basis for setting min-
imum therapeutic dose specifications for the anal-
ysis. The minimum dose requirements are listed in
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Table 1. AHCPR guidelines specify that antide-
pressant drug therapy should continue for be-
tween 4 and 9 months. For this analysis, the du-
ration of therapy required for “completed”
treatment was set at 180 days (6 months).
Adequate dose and duration was established in
this study using two methods. The first method was
applied separately to the stream of prescription
data available for the patient’s initial antidepressant
and to each added medication. This approach calcu-
lated the total milligrams of medication dispensed
for each prescription (doses dispensed times strength)
which was then divided by the calculated number of
days between fill dates. The resulting estimate of
average daily dose was then divided by the mini-
mum therapeutic daily dose specified in Table 1
for the medication dispensed to derive the relative
effective dose achieved for each prescription filled.
In order to allow for dose titration, a patient was
considered to have achieved a minimum therapeu-
tic dose for the first initial prescription filled if the
estimated effective dose exceeded 0.5, or 50%, of
the drug’s minimum therapeutic dose. The second
prescription was deemed therapeutic if the esti-
mated effective dose exceeded 0.75. Each subse-
quent prescription was deemed therapeutic if the
calculated effective dose exceeded 0.9, thus allow-
ing for limited early and late refills.
The number of therapeutic days achieved on
the initial antidepressant dispensed was obtained
by adding the number of days covered by each
prescription until the effective dose dropped be-
low target levels. If a second medication was used
prior to 45 days from the last refill of the initial
prescription, the therapeutic days achieved on
subsequent medications were included in the total
count of therapeutic days. The count of therapeu-
tic days on the second medication followed the al-
gorithm described above, again allowing for titra-
tion of the second medication. A similar procedure
was applied to the second added medication.
However, if a gap in excess of 45 days occurred
between the last prescription filled of the preced-
ing medication and an added antidepressant, the
number of therapeutic days was limited to that
achieved on the preceding drug or drugs. A sepa-
rate count of therapeutic days achieved on added
medications was also undertaken using the same
criteria, regardless of any gap that may have tran-
spired between medications, as a measure of treat-
ment completion with secondary medications.
The method outlined above may not represent
an accurate count of therapeutic days because of
early refills, or augmentation and titration of the
initial prescription with the same medication at a
different strength. Therefore, a second method of
calculating therapeutic days was developed which
divides the total milligrams of medication dis-
pensed (regardless of strength) by the total days
covered by all prescriptions for a single medica-
tion, accounting for overlapping coverage and
breaks in coverage in excess of 15 days. As before,
this aggregate calculation of average daily dose
was divided by the minimum daily therapeutic
dose specified in the AHCPR guidelines to derive
the relative effective dose achieved. If this value
exceeded 0.9, then the entire period covered by
the prescription(s) was identified as therapeutic.
Similar calculations were undertaken for the first
two added medications if the patient changed the
medication used.
An adequate course of therapy (treatment com-
pletion) was defined as the patient having achieved
180 consecutive days of therapeutic dosing by ei-
ther method of calculation, whether these days
were achieved on the initial medication prescribed
or on an added medication. A dichotomous vari-
able indicating completion of therapy was used as
an independent variable in regression models of
post-treatment costs. A sensitivity analysis was
conducted to determine if patients who complete
therapy on a second antidepressant exhibit a dif-
ferent pattern of post-treatment costs relative to
noncompleters than patients who complete ther-
apy without a change in medications. A determi-
nation was made whether the patient completed
an adequate course of therapy on their initial or
secondary medication and these dichotomous vari-
ables were used in regression models of post-treat-
ment cost.
 
Table 1
 
Potential study population by initial therapy
 
Type of initial therapy
Minimum
therapeutic dose
specification
(mg/day)
Final study
population 
(N 
 

 
 1648)
Tricyclics with MDD diagnosis 970
Imipramine 75 176
Amitriptyline/Perphenazine 75 144
Amitriptyline 75 333
Desipramine 75 114
Protriptyline 20 7
Nortriptyline 40 196
Heterocyclics 311
Trazodone 150 308
Bupropion 255 3
Paroxetine 20 97
Sertraline 50 130
Fluoxetine 10 140
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Descriptive Statistics
 
Table 2 displays the population characteristics by
type of initial therapy used. In general, all five
treatment groups appear quite similar with a few
notable exceptions. SSRI patients tend to be less
urban and to have higher drug expenditures in the
prior period than either TCA or heterocyclic pa-
tients. Even with the higher drug expenditures,
SSRI patients were more likely to fill all of their
prescriptions at a single pharmacy. SSRI patients
were also more likely to have experienced a prior
episode of antidepressant therapy than the other
treatment groups. However, fluoxetine, TCA, and
heterocyclic patients were more likely to have used
the services of a psychiatrist than sertraline or par-
oxetine patients. Finally, sertraline, paroxetine, and
heterocyclic patients had higher levels of total costs
in the prior six months ($3678–$4678) than TCA
patients ($3299) or fluoxetine patients ($3011).
Some of these differences are related to the higher
rates of hospitalizations for heterocyclic and ser-
traline patients in the period prior to treatment.
 
Statistical Methods
 
Multivariate ordinary least-squares (OLS) regres-
sion analyses were used to investigate the impact
of the patient having achieved adequate dose and
duration of antidepressant drug therapy on health
care costs. In order to control for baseline differ-
ences across alternative antidepressants, all mod-
els used independent variables based on data re-
corded on the paid claims. Demographic data
included age, gender, urban or rural residence,
and year in which treatment was initiated (time
trend). The prior use of health care, including the
use of psychiatrists, psychologists and mental
health centers, was measured as the total pay-
ments for these services during the pretreatment
period aggregated by provider type. Dichotomous
diagnostic mix variables were created based on the
ICD-9 codes recorded on services consumed in the
pretreatment period. The patient’s use of medica-
tions for anxiety, prescribed narcotics, and hyp-
notics in the pretreatment period were measured
by dichotomous variables based on paid claims
for drugs in these therapeutic classes. Similar drug
profile variables were created indicating the use of
medications for heart disease, hypertension, hor-
mone replacement therapy, arrhythmia, and Par-
kinson’s disease, based on the patient’s prescrip-
tion claims in the pre- and post-treatment periods.
A dichotomous variable was created indicating
whether the patient used a single pharmacy for all
prescriptions filled during the pre- and post-treat-
ment periods.
Because a new episode was defined after each
break in therapy in excess of 6 months, each pa-
tient could have multiple new episodes of antide-
pressant therapy. A variable was created that
counted the number of antidepressant treatment
episodes that preceded each episode in the study.
While this variable is not an accurate measure of
the true number of prior episodes due to the trun-
cation of the data prior to January 1987, it does
provide some measure of recurrent depression.
Any reduction in post-treatment health care
costs associated with adequate dose and duration
antidepressant drug therapy will likely be offset by
increased drug costs, thus making the impact of
 
Table 2
 
Baseline characteristics of study population by initial therapy used
 
Characteristic
Tricyclic
(N 
 

 
 970)
Heterocyclic 
(N 
 

 
 311)
Paroxetine
(N 
 

 
 97)
Sertraline
(N 
 

 
 130)
Fluoxetine
(N 
 

 
 140)
Age (years)* 45.7 (14.8) 46.5 (15.8) 53.6 (18.5) 51.9 (18.2) 49.1 (17.5)
Gender (1 
 

 
 F) 77.2% 78.5% 63.9% 74.6% 77.9%
Urban county* 74.2% 72.4% 44.3% 72.3% 62.9%
Prior Use of Healthcare
Ambulatory $2361 $2815 $2940 $3502 $1998
Drugs* $250 $250 $480 $519 $424
Hospitalized in prior period* 4.5% 8.0% 2.1% 5.4% 1.4%
Hospital costs $535 $831 $162 $542 $434
Hospital days 0.5463 0.8489 0.1649 0.5538 0.4429
Other costs $261 $326 $173 $215 $257
Total costs $3299 $4084 $3678 $4678 $3011
Prior episodes 0.3000 0.2958 0.3608 0.3769 0.4071
Psychiatry* 25.5% 32.2% 10.3% 13.1% 27.9%
Psychologist 5.9% 6.4% 2.1% 4.6% 5.7%
Mental Health Center 3.9% 5.8% 3.1% 4.6% 2.1%
Used 1 Pharmacy* 12.0% 12.2% 21.7% 28.5% 20.0%
 
*Statistically significant (
 
P
 
 
 
 .05) using chi-square for category variables and ANOVA for continuous and counting data. Standard deviations for age in parentheses.
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completed therapy on total costs ambiguous. In
order to clarify the effects of an adequate course
of therapy on post-treatment health care costs, the
analysis focused on the components of health care
costs, including total costs net of drug costs. The
log of costs was used as a dependent variable in
addition to actual costs to control for non-nor-
mality.
Sensitivity analyses were conducted in which
the impact of achieving adequate dose and dura-
tion on an initial course were compared to com-
pletion on a secondary course of antidepressant
therapy. Both effects were measured relative to
noncompleters. In these sensitivity analyses, it was
hypothesized that the need to add a second antide-
pressant medication would be associated with in-
creased costs or reduced savings.
An intent-to-treat analysis was conducted to
compare outcomes across alternative medications
when used as initial therapy. Logistic regression
techniques were used to estimate the impact of the
initial medication selection on the probability that
a patient achieved adequate dose and duration of
therapy. Cost models were then estimated using
both actual costs and log costs. Patients who used
a tricyclic antidepressant as their initial therapy
were defined as the index population for the in-
tent-to-treat analyses.
 
Results
 
Cost Impacts of Adequate Dose and Duration
 
Only 358 of 1648 MDD-patients (21.7%) with a
new episode of antidepressant therapy achieved 6
months of uninterrupted therapeutic dosing. Data
describing these two populations are provided in
Table 3. Patients who achieved adequate dose and
duration were more likely to have used an antipsy-
chotic medication or to have added a second or
third drug while continuing their initial therapy (aug-
menters), though they may have dropped their ini-
tial therapy at a later date. Patients who did not
achieve adequate dose or duration were more
likely to have added these medications while ter-
minating their initial therapy (switchers).
Post-treatment costs for patients with adequate
dose and duration of therapy were lower for all
components of costs except drug costs and the
costs of other services, including dental services.
These data, which were not adjusted for differ-
ences in the prior use of health care or other fac-
tors, indicate that adequate dose and duration of
antidepressant therapy reduces total costs by
nearly $1900 in the first post-treatment year, pri-
marily due to lower ambulatory care costs ($1830).
Table 4 summarizes the estimated impact on
actual costs and log-costs of adequate dose and
duration of antidepressant therapy. The first col-
umn lists results for the analyses in which all com-
pleters are considered as a single group. The last
two columns list results for the analyses in which
patients who achieved adequate dose and duration
on their initial medication or on a subsequent ther-
apy are compared separately to noncompleters.
The results for all completers combined display
a pattern of decreased ambulatory care costs
(
 

 
$1296, 
 
P
 
 
 

 
 .0110), nursing home costs (
 

 
$348,
 
P
 
 
 

 
 .2748) and hospital costs (
 

 
$230, 
 
P
 
 
 

 
 .4190)
offset by higher drug costs (
 

 
$323, 
 
P
 
 
 

 
 .0282).
Adequate dose and duration of therapy was asso-
ciated with a significant reduction in total costs
(
 

 
$1487, 
 
P
 
 
 

 
 .0479). The results in the models
using the log-cost were consistent with the above
results, although the estimated effects of adequate
dose and duration of therapy on net and total
costs were not statistically significant.
As expected, the savings associated with an ad-
equate course of therapy were more pronounced
when completion on an initial course of therapy
was compared separately to noncompleters from
completion on secondary courses of therapy. The
reductions associated with achieving adequate
therapy without a break in therapy were negative
 
Table 3
 
Descriptive statistics for secondary drug use and 
post-treatment use of health care
 
Adequate 
dose and
duration
(N 
 

 
 358)
Interrupted, 
terminated
or low
dose therapy 
(N 
 

 
 1290)
Secondary drug use
Augmented with AD 13.7%* 6.1%*
Switched AD 16.2%* 30.0%*
Augmented with antipsychotic 12.0%* 7.7%*
Tertiary drug use
Augmented with AD 4.5% 3.7%
Switched AD 1.1%* 4.3%*
Post-treatment use of services
Ambulatory care $4209* $6039*
Drugs $1639* $1132*
Admitted to LTC facility 0.8% 1.6%
Nursing home care $235 $595
Hospitalized 6.2% 6.1%
Hospital costs $544 $748
Other services $746 $713
Costs net of drug costs $5735* $8095*
Total costs $7374* $9227*
 
*Statistically significant differences (
 
P
 
 
 
 .05) using chi-square for proportions
and t-tests for average cost by type of service.
 The Role of SSRI Antidepressants
 
275
 
and significant for ambulatory care costs (
 

 
$1499,
 
P
 
 
 

 
 .0080), net cost (
 

 
$2320, 
 
P
 
 
 

 
 .0033) and to-
tal costs (
 

 
$2080, 
 
P
 
 
 

 
 .0125).
Patients who achieved adequate dose and dura-
tion on a secondary course of antidepressant ther-
apy displayed smaller estimated savings in ambu-
latory care compared to noncompleters, whose
savings were offset by much higher drug costs
than patients who completed their initial course of
therapy ($608 versus $239). As a result, patients
who achieved an adequate dose and duration on a
secondary course of therapy displayed costs roughly
equivalent to noncompleters, though none of these
estimates were statistically significant with the ex-
ception of higher drug costs. The results from the
analyses that used log-costs as a dependent vari-
able were generally consistent with these results.
Several other results can be derived from the re-
gression models of total costs. Patients who pa-
tronized one pharmacy for all of their prescrip-
tions were estimated to use $2951 less in total
health care in the post-treatment year than pa-
tients who used two or more pharmacies (
 
P
 
 
 

 
.0010). This “one-pharmacy” effect is consistent
with previous results using Medi-Cal data that
found single pharmacy cost reductions of $1242
per year for antihypertensive patients [25]; $1822
per year for patients treated for onychomycosis
[26]; and $550 to $580 over 3 months for cimeti-
dine patients using concomitant medications with
significant adverse drug reaction potential [27].
Prior use rates for health care services are
highly predictive of future costs. For example,
each dollar spent on prescription drugs in the
prior 6 months is correlated with a $6.99 increase
in costs in the following year (
 
P
 
 
 

 
 .0001). Corre-
sponding results for hospital and ambulatory care
spending in the prior period are much smaller, but
statistically significant ($0.14, 
 
P
 
 
 

 
 .0175 and
$0.38, 
 
P
 
 
 

 
 .0001, respectively).
 
An Intent-to-Treat Analysis of Alternative
Initial Therapies
 
An intent-to-treat analysis was conducted which
compared outcomes based on the medication used
as initial therapy. Five alternative initial antide-
pressant therapies were compared: TCAs, hetero-
cyclics, paroxetine, sertraline, and fluoxetine. These
data must be interpreted with caution given the
relatively small number of patients treated with
each of the three SSRI antidepressants and the rel-
atively short time for which paroxetine and sertra-
line were available to Medi-Cal patients.
The drug profile data in Table 5 indicate im-
portant differences across alternative therapies.
First, termination rates after two prescriptions
vary widely, ranging from nearly 71.2% for par-
oxetine to 28.6% for fluoxetine, which also had
the largest proportion of patients purchasing six
or more prescriptions (42.1%). The same pattern
appears for early terminations even after account-
ing for changes in the medication used.
Early terminations of initial therapy were a ma-
jor factor in determining if the patient achieves an
adequate course of antidepressant therapy; the
other factor was under-dosing. Not surprisingly,
approximately 13% to 14.5% of patients initiat-
ing therapy with a tricyclic or heterocyclic antide-
pressant achieved an adequate course of therapy
on their initial medication, with an additional 4%
to 5% of patients completing therapy on a second-
ary drug. The completion rates for sertraline and
 
Table 4
 
Estimated effects of adequate dose and duration: actual costs and log-costs results, MDD patients only (N 
 

 
 1648)
 
Type of service
Adequate dose and
duration of therapy
Adequate dose and 
duration on initial drug
Adequate dose and 
duration on added drug
Actual costs 358 Completers 276 Completers 82 Completers
Ambulatory costs
 

 
$1296 (
 
P
 
 
 

 
 .0110)
 

 
$1499 (
 
P
 
 
 

 
 .0080)
 

 
$614 (
 
P
 
 
 

 
 .5249)
Drug costs
 

 
$323 (
 
P
 
 
 

 
 .0282)
 

 
$239 (
 
P
 
 
 

 
 .1434)
 

 
$608 (
 
P
 
 
 

 
 .0295)
Hospital admission (odds ratio) 1.115 (
 
P
 
 
 

 
 .6711) 1.146 (
 
P
 
 
 

 
 .6326) 1.023 (
 
P
 
 
 

 
 .9632)
Hospital costs
 

 
$230 (
 
P
 
 
 

 
 .4190)
 

 
$314 (
 
P
 
 
 

 
 .3194)
 

 
$53 (
 
P
 
 
 

 
 .9212)
LTC admission (odds ratio) 0.708 (P  .5897) 0.556 (P  .4394) 1.583 (P  .6707)
Nursing home costs $348 (P  .2743) $551 (P  .1181) $336 (P  .5771)
Other costs $62 (P  .3080) $43 (P  .5218) $126 (P  .2775)
Costs net Rx costs $1811 (P  .0109) $2320 (P  .0033) $98 (P  .9417)
Total costs $1487 (P  .0479) $2081 (P  .0125) $510 (P  .7201)
Log-costs 
Ambulatory costs 23.5% (P  .0104) 34.2% (P  .0008) 12.6% (P  .4693)
Drug costs 70.4% (P  .0001) 69.7% (P  .0001) 72.6% (P  .0001)
Other costs 17.9% (P  .3655) 18.3% (P  .4041) 16.6% (P  .6590)
Cost net Rx costs 12.3% (P  .0922) 17.7% (P  .0289) 5.8% (P  .6726)
Total costs 6.4% (P  .2500) 3.3% (P  .5904) 16.7% (P  .1119)
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paroxetine patients were similar to the older anti-
depressants (18.7% and 9.3%, respectively), and
5% to 6% of completions were achieved on an
added antidepressant. In comparison, 55% of pa-
tients treated with fluoxetine achieved an ade-
quate dose and duration of antidepressant ther-
apy, either on fluoxetine (50.7%) or on a second
antidepressant (4.3%).
A multivariate logistic analysis of the likelihood
of completing an adequate course of therapy was
estimated to measure the relative impact of the ini-
tial medication prescribed using TCA patients as
the comparison group. The results of the logistic
analysis are summarized as odds ratios with re-
spect to TCAs and are listed in Table 5. The odds
ratio results indicate that fluoxetine patients were
roughly 5.8 times more likely to achieve adequate
dose and duration of therapy relative to TCA
medications, taking into account demographic, di-
agnostic, and prior use characteristics of the pa-
tient (P  .0001). Sertraline patients were 62%
more likely to achieve adequate dose and duration
than TCA patients (odds ratio  1.622, P 
.0447). Patients prescribed paroxetine or hetero-
cyclics as initial therapy were not statistically dif-
ferent than TCA patients.
The observed differences in the likelihood of
achieving adequate dose and duration across alter-
native SSRIs are unexpected given the extensive
clinical trial data for these products which show
little difference in efficacy or side-effect profiles.
However, the observed differences in initial ther-
apy completion rates favoring fluoxetine, and to a
lesser extent sertraline, are supported by other
data in Table 5. When only those patients using a
psychiatrist before or soon after the date of the
initial antidepressant prescription were consid-
ered, completion rates for TCAs and heterocyclics
as the initial medication improved to 18% and
26%, respectively, while the paroxetine comple-
tion rate did not improve. However, these rates
still lagged the corresponding rate for fluoxetine
(56%) and sertraline, which improved signifi-
cantly to 53%. The rates of augmentation, switch-
ing, and antipsychotic drug use were also consis-
tent with the differential in adequate dose and
duration rates across initial therapies. Patients
who were prescribed fluoxetine as initial therapy
switched to a second antidepressant in 10% of
treatment episodes. Switch rates for all other anti-
depressants ranged between 24.4% (heterocyclics)
and 30.1% (TCAs). The fluoxetine augmentation
rate (5.7%) was lower than that found for TCA
and heterocyclic patients (8–10%), and higher
Table 5 Summary statistics for adequacy of antidepressant therapy by initial therapy used
Characteristic
Tricyclic 
(N  970)
Heterocyclic
(N  311)
Paroxetine 
(N  97)
Sertraline 
(N  130)
Fluoxetine 
(N  140)
Number of initial prescriptions filled (%):
1 33.5 31.5 48.5 38.5 14.3
2 19.0 16.4 22.7 11.5 14.3
3 9.4 8.4 7.2 7.7 7.1
4 5.8 5.5 3.1 7.7 12.9
5 3.7 3.9 5.2 1.5 9.3
6 or more 28.7 34.4 13.4 33.1 42.1
Stopped initial drug 2 prescriptions,
no added Rx (%) 24.1 21.5 46.4 23.9 21.4
Adequate dose and duration (%)
Any medication 18.1 18.7 14.4 25.4 55.0
Initial drug 13.0 14.5 9.3 19.2 50.7
Secondary drug 5.1 4.2 5.1 6.2 4.3
Odds ratio with respect to TCAs n.a. 0.995 (P  .9753) 0.795 (P  .4027) 1.622 (P  .0447) 5.762 (P  .0001)
Adequate dose and duration: psychiatry
only (%) 17.8 (N  247) 26.0 (N  100) 10.0 (N  10) 52.9 (N  17) 56.4 (N  39)
Adequate dose and duration: episodes
after 1 July 1994 (%) 19.4 (N  216) 14.7 (N  68) 38.5 (N  26) 33.3 (N  54) 47.5 (N  40)
Adequate dose and duration: early 
episodes (%) n.a. n.a. 6.9 (N  72) 16.2 (N  68) 59.5 (N  74)
Use of second drug (%)
Augmented with AD 8.1 10.0 3.1 5.4 5.7
Switched AD 30.1 24.4 26.8 28.5 10.0
Used antipsychotic 9.3 12.5 3.1 3.9 3.6
Used of third drug (%)
Augmented with AD 4.5 3.5 4.1 0.8 2.9
Switched AD 4.6 3.9 1.0 0.8 0.7
Adequate dose as second therapy 6.9 (N  375) 7.6 (N  131) 0.0 (N  26) 22.7 (N  22) 36.8 (N  19)
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than that found for paroxetine (3.1%) and sertra-
line (5.4%). The SSRIs had similar rates of aug-
mentation with an antipsychotic medication within
60 days of the initiation of therapy. Finally, in our
sample, fluoxetine was found to be more likely to
achieve adequate dose and duration when used as
a secondary medication (35.3%) compared to all
other alternative antidepressants (0–20%).
One possible explanation for the differences in
the likelihood of achieving an adequate course of
therapy across the SSRIs is the length of time each
product was available for physicians to become fa-
miliar with their use. This hypothesis is supported
by the completion rate data derived for those epi-
sodes of drug therapy initiated after July 1, 1994
(the last year for which complete data were avail-
able). The completion rates for patients treated
during this period were 38.7% for paroxetine (N 
26), 33.3% for sertraline (N  54), and 47.5%
for fluoxetine (N  40). Fluoxetine performed
much better, however, when 70–80 of the earliest
episodes of care are compared for each product.
The rate of adequate dose and duration for these
episodes are 59.5% for fluoxetine (N  74),
16.2% for sertraline (N  68), and 6.9% for par-
oxetine (N  72).
The differences between fluoxetine and TCAs
as initial therapy observed here are supported by
other studies. The cumulative rate at which TCA
and fluoxetine patients switched or augmented
their initial therapy with a second antidepressant
(38.4% and 18.0%, respectively) are very similar
to rates reported by Simon et al. [18]. In a pro-
spective comparison of TCAs to fluoxetine con-
ducted at Group Health Cooperative of Puget
Sound, 48% of desipramine patients, 43% of imi-
pramine patients, and 20% fluoxetine patients
were found to have switched therapies within 6
months.
Multivariate analyses of cost effects associated
with the type of initial therapy prescribed are re-
ported in Table 6. Patients prescribed a TCA as
initial therapy again served as the comparison
group in these analyses. Fluoxetine and sertraline
were the only alternatives to TCAs for which sta-
tistically significant cost-savings were demonstrated.
In the analysis of actual costs, fluoxetine as initial
therapy was associated with significant reductions
in ambulatory care costs ($2125, P  .0070),
net costs ($3572, P  .0012), and total costs
($3524, P  .0024) during the first post-treat-
ment year relative to TCAs. These results were
confirmed in the log-cost analyses with the excep-
tion of total costs (13.1%, P  .1275). Sertra-
line was found to reduce nursing home costs
($1026, P  .0487), other costs ($230, P 
.0215) and the log of net costs (29%, P  .0149)
and other costs (111%, P  .0006). Paroxetine
as an alternative to TCAs as initial therapy dis-
played lower total costs in the analyses using ac-
tual costs, though none of these estimated effects
were statistically significant. Heterocyclics were
estimated to increase drug costs relative to TCAs
in both the actual cost and log-cost analyses.
Sensitivity Analyses
Four sensitivity analyses were performed. First,
Thompson et al. [28] found that 19.1% of 1200
SSRI patients terminated therapy early and were
low-cost patients relative to patients who switched
or augmented their therapy. An analysis was con-
ducted using the augmented sample in which pa-
tients who terminated antidepressant therapy after
only one to two prescriptions for their initial med-
Table 6 Comparative cost effects by initial type of therapy by type of service (TCAs used as a comparison)
Type of service Heterocyclics (N  311) Paroxetine (N  97) Sertraline (N  130) Fluoxetine (N  140)
Actual costs
Ambulatory costs $429 (P  .4418) $14 (P  .8891) $279 (P  .7381) $2125 (P  .0070)
Drug costs $56 (P  .7274) $891 (P  .0019) $391 (P  .1054) $48 (P  .8324)
Hospital admissions (odds ratio) 1.043 (P  .8702) 0.161 (P  .0765) 0.990 (P  .9805) 0.353 (P  .0855)
Hospital costs $213 (P  .4939) $220 (P  .6917) $36 (P  .9377) $728 (P  .0977)
LTC admissions (odds ratio) Model not estimable Model not estimable Model not estimable Model not estimable
LTC costs $95 (P  .7939) $1158 (P  .0614) $1026 (P  .0487) $690 (P  .1598)
Other costs $135 (P  .0445) $5 (P  .9685) $230 (P  .0215) $28 (P  .7659)
Costs net Rx costs $446 (P  .5666) $1386 (P  .3166) $941 (P  .4198) $3572 (P  .0012)
Total costs $502 (P  .5412) $495 (P  .7348) $550 (P  .6547) $3524 (P  .0024)
Log-costs
Ambulatory costs 13.8% (P  .1666) 20.4% (P  .2517) 11.5% (P  .4420) 65.5% (P  .0001)
Drug costs 03.9% (P  .4865) 13.9% (P  .1614) 50.5% (P  .0001) 49.5% (P  .0001)
Other costs 33.8% (P  .1174) 35.2% (P  .3581) 110.8% (P  .0006) 62.1% (P  .0415)
Cost net of Rx costs 12.9% (P  .1084) 5.6% (P  .6941) 29.0% (P  .0149) 42.2% (P  .0002)
Total costs 10.8% (P  .0768) 4.8% (P  .6535) 0.8% (P  .9337) 13.1% (P  .1275)
278 McCombs et al.
ication were analyzed as a separate group. The
early termination rate in the Medi-Cal population
studied here was 24.7%. Including these patients
in the analysis as a separate group increased the
total cost-savings associated with an adequate course
of antidepressant therapy by approximately $85.
Early termination of antidepressant therapy was
correlated with lower hospital costs ($604, P 
.0353) and costs for other services ($132, P 
.0320); however, total costs were not significantly
affected ($275, P  .7165).
A second sensitivity analysis was conducted in
which the 28 patients with very high use of ambu-
latory or hospital services were included in the
analysis. Including these patients had two effects
in the analyses of the cost effects of completed
therapy. First, the savings associated with com-
pleted therapy increased from $1487 (P 
.0479) to $2664 (P  .0881). However, the
variance in the data increased significantly, thus
reducing the statistical significance of some pa-
rameter estimates. In the intent-to-treat analyses,
the savings associated with all alternatives to the
TCAs increased with the exception of fluoxetine,
which was reduced from $3524 (P  .0024) to
$1928 (P  .4208). None of the alternatives
were found to be statistically different from the
TCAs in terms of total costs and fluoxetine was
found to have the largest savings.
The use of antipsychotic medications in the
post-treatment period was higher in the TCA and
heterocyclic patient populations (Table 5), sug-
gesting that patients with psychotic depression
were treated predominately with these products.
Since concomitant psychoses are likely to signifi-
cantly increase costs, a sensitivity analysis was
conducted in which antipsychotic drug use in the
post-treatment period was included into the mod-
els of post-treatment cost. While antipsychotic
drug use in the post-treatment period is correlated
with significantly higher hospital and nursing
home costs in the post-treatment period, inclusion
of this dichotomous variable in the cost models
did not change the estimated impact of completion
of therapy or the intent-to-treat analyses.
Finally, SSRI patients included in the primary
models reported above were not screened for
whether an MDD diagnosis had been recorded on
their paid claim file. A sensitivity analysis was
conducted in which all cost and completion mod-
els were re-estimated with only confirmed MDD
patients included in the analyses. The results from
these models, including the intent-to-treat analyses,
parallel closely the results reported above, although
the level of statistical significance has been reduced
due to the reduction in available observations.
Discussion
Only 22% of Medi-Cal MDD patients studied
here achieved an adequate course of therapy in
terms of dose and duration. This disappointing
completion rate is not unexpected. Katon et al.
[29] found that 50% of HMO members achieved
adequate dose and duration for 90 days or more.
The lower completion rates in the Medi-Cal popu-
lation are likely due to the longer period of time
used to define completed therapy and the charac-
teristics of a Medicaid population. For example,
educational attainment and patient knowledge
concerning the disease state and prescribed ther-
apy have long been known to be positively corre-
lated with patient compliance with drug therapy
[30]. Antidepressant drug therapy completion
rates may be higher in non-Medicaid populations.
This analysis found a correlation between an
adequate course of antidepressant therapy and
lower ambulatory health care costs, which were
offset by higher drug costs. The effect of com-
pleted therapy on overall health care costs appears
to indicate savings, though these results were not
always statistically significant. Additional study is
required with a larger sample of patients to verify
the cost savings associated with adequate dose
and duration as measured in this study.
The data for the three SSRI antidepressants
studied are less compelling due to the limited sam-
ple size available for analysis and the relatively
short time period in which paroxetine and sertra-
line were available to physicians. In the limited
sample of SSRI patients, however, fluoxetine dem-
onstrated significantly higher rates of adequate
dose and duration as initial therapy than all other
alternatives studied. These results were confirmed
in a multivariate logistic regression analysis in
which fluoxetine was estimated to increase the
likelihood of achieving an adequate course of
therapy relative to TCAs by a factor of 5.8. The
use of multivariate estimation procedures permit-
ted factors such as baseline differences in cohort
age or severity to be controlled statistically. While
confirmation of the differences between the SSRIs
is necessary due to the limited sample available for
this analysis, the data required for such confirma-
tion are readily available to most managed care
plans and HMOs. At a minimum, simple counts
of the number of prescriptions filled and medica-
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tion switch rates can be easily observed from
pharmacy data.
Similarly, the results indicating that fluoxetine
used as initial therapy reduced the total cost of
treating MDD patients when compared to TCAs
can be questioned due to small sample size and
possible unobserved differences between these pa-
tient groups. Two factors tend to temper these
concerns. First, the estimated cost effects associ-
ated with fluoxetine are consistent with expecta-
tions given fluoxetine’s higher rate of adequate
dose and duration of therapy and the estimated ef-
fects of completed therapy on costs. Specifically,
fluoxetine patients experienced lower ambulatory
care costs that were partially offset by increased
drug costs. Second, the models used to estimate
the cost effects of alternative therapies to TCAs
controlled for prior use, patient demographics,
and baseline drug profiles and diagnostic data. Fi-
nally, the other SSRIs were also associated with
lower costs relative to TCAs though the estimated
cost-savings were not statistically significant.
Finally, analyses based on paid claims data
have significant limitations that may affect the in-
ternal validity of these results. First, the limited re-
liability of diagnostic data recorded on paid claims
makes it difficult to limit the analysis to MDD pa-
tients only, or to fully account for possible differ-
ences in severity and comorbidities across pa-
tients. Biased estimates of differences across
antidepressants will result if drug selection is cor-
related with severity of illness or health status.
While the statistical models specified in this analy-
sis include multiple independent variables de-
signed to account for these differences, the extent
of possible residual bias is unknown. Second, pa-
tients who lost their Medi-Cal eligibility during
the post-treatment period were dropped from the
analysis due to missing data concerns. Given the
debilitating effects of depression [21], it is likely
that patients who completed drug therapy exhib-
ited a higher likelihood of exclusion due to miss-
ing data. If this is the case, the observed rate of
completed therapy (22%) is biased downward, as
are the estimates of potential cost savings due to
completed therapy.
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